Last update 27 Jun 2026

SIM-0689

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
SIM 0689, SIM0689
Target
PD-1 x VEGF
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Metastatic Solid TumorAdvanced Malignant Solid NeoplasmSolid tumor
Inactive Indication-
Originator Organization
Simcere Zaiming Pharmaceutical Co., Ltd.Simcere Zaiming Pharmaceutical Co., Ltd.
Active Organization
Simcere Pharmaceutical Group Ltd.Simcere Pharmaceutical Group Ltd.Shanghai Xiansheng Zaiming Technology Co., Ltd.Jiangsu Simcere Pharmaceutical Co., Ltd.Jiangsu Simcere Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with SIM-0689
NCT07660432
/ Not yet recruitingPhase 1
Phase I First-in-Human, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with SIM-0689
Login to view more data
100 Translational Medicine associated with SIM-0689
Login to view more data
100 Patents (Medical) associated with SIM-0689
Login to view more data
100 Deals associated with SIM-0689
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Solid TumorPhase 1
China
Jiangsu Simcere Pharmaceutical Co., Ltd.Jiangsu Simcere Pharmaceutical Co., Ltd.
01 Jul 2027
Advanced Malignant Solid NeoplasmPhase 1
China
Shanghai Xiansheng Zaiming Technology Co., Ltd.
22 Jun 2026
Solid tumorPreclinical
China
Simcere Pharmaceutical Group Ltd.Simcere Pharmaceutical Group Ltd.
01 Feb 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free